HeartBeam Wins CVI 2022 Innovation Summit Award
28 July 2022 - 10:31PM
Business Wire
Annual Awards Program Recognizes
State-of-the-Art Cardiac Technologies
HeartBeam, Inc. (NASDAQ: BEAT), a developmental stage
digital healthcare company with a proprietary ECG telemedicine
technology for heart attack detection, was selected as winner of
the annual Cardiovascular Innovations (CVI) 2022 Innovation Summit
and Shark Tank Competition held on July 21, 2022, in Denver,
Colorado. The CVI annual conference focuses on innovative health
solutions for cardiology clinicians who participate in the care of
patients with coronary, peripheral and structural cardiovascular
diseases.
The Company was invited to participate by CVI board member,
Subhash Banerjee, MD. HeartBeam’s presentation, “Medical Grade
Heart Attack Detection,” was delivered by Jon Hunt, PhD, Chief
Business Officer, discussing the Company’s HeartBeam AIMI™ platform
designed to aid in more precise heart attack diagnosis. HeartBeam
was among several companies presenting cutting-edge technology
advancements and was judged by veterans from leading companies as
well as expert cardiologists.
The HeartBeam AIMI™ platform technology is anticipated to assist
health care professionals in identifying patients who present with
chest pain to facilitate rapid detection of a heart attack and
determine an appropriate treatment regimen. Chest pain is the
second most common reason for an emergency department visit, with
high costs associated with these visits. HeartBeam’s technology may
offer more accurate heart attack detection to triage patients and
expedite treatment. The HeartBeam technology platform has not yet
been evaluated by the FDA and is not approved for clinical use in
the USA or other global geographies.
“We are proud that HeartBeam has been recognized for our unique
approach to heart attack diagnosis,” said Branislav Vajdic, CEO and
founder of HeartBeam. “Our goal is to provide a solution that
offers both healthcare professionals and patients peace of mind
regarding their diagnosis and treatment plan.”
About HeartBeam, Inc.
HeartBeam, Inc. (NASDAQ: BEAT) is a development stage digital
healthcare company with proprietary ECG telemedicine technology
that will redefine the way high risk cardiovascular patients are
diagnosed in an ambulatory setting at any time and any place. Its
breakthrough solution employs a reusable, credit card sized, 3D
vector ECG recording device and cloud-based software capable of
assisting a physician in diagnosing a wide range of cardiovascular
disease. HeartBeam is initially focusing on a huge unmet need of
helping diagnose heart attacks in patients outside of a medical
institution. No single lead ECG technology can offer this value to
patients and their physicians. This underserved market is several
times larger than the cardiac arrhythmia detection market based on
the prevalence of patients with coronary artery disease at high
risk of heart attack. For more information, visit
www.heartbeam.com.
Forward-Looking Statements
All statements in this release that are not based on historical
fact are "forward-looking statements." While management has based
any forward-looking statements included in this release on its
current expectations, the information on which such expectations
were based may change. Forward-looking statements involve inherent
risks and uncertainties which could cause actual results to differ
materially from those in the forward-looking statements, as a
result of various factors including those risks and uncertainties
described in the Risk Factors and in Management’s Discussion and
Analysis of Financial Condition and Results of Operations sections
of our in our Forms 10-K, 10-Q and other reports filed with the SEC
and available at www.sec.gov. We urge you to consider those risks
and uncertainties in evaluating our forward-looking statements. We
caution readers not to place undue reliance upon any such
forward-looking statements, which speak only as of the date made.
Except as otherwise required by the federal securities laws, we
disclaim any obligation or undertaking to publicly release any
updates or revisions to any forward-looking statement contained
herein (or elsewhere) to reflect any change in our expectations
with regard thereto or any change in events, conditions or
circumstances on which any such statement is based.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220728005136/en/
Media and Investor Relations Contact: Chris Tyson
Executive Vice President MZ North America Direct: 949-491-8235
BEAT@mzgroup.us www.mzgroup.us
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From Apr 2024 to May 2024
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From May 2023 to May 2024